- Report
- February 2022
- 210 Pages
Global
From €6646EUR$7,500USD£5,724GBP
- Report
- April 2024
- 190 Pages
Global
From €3390EUR$3,825USD£2,919GBP
€3988EUR$4,500USD£3,434GBP
- Report
- July 2024
- 231 Pages
Global
From €7045EUR$7,950USD£6,067GBP
- Report
- August 2022
- 111 Pages
Global
From €4209EUR$4,750USD£3,625GBP
- Report
- June 2022
- 120 Pages
Global
From €4209EUR$4,750USD£3,625GBP
- Report
- January 2024
- 138 Pages
United States
€3367EUR$3,800USD£2,900GBP
- Report
- April 2018
United States
From €7085EUR$7,995USD£6,101GBP
- Report
- January 2024
- 87 Pages
Global
From €3500EUR$4,231USD£3,120GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$4,231USD£3,120GBP
Certolizumab is a monoclonal antibody used to treat immune disorders. It is used to treat a variety of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking the action of a protein called tumor necrosis factor (TNF), which is involved in the body's inflammatory response. Certolizumab is administered as an injection, usually once every two weeks.
Certolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2008. It is one of several drugs used to treat immune disorders, and is often used in combination with other medications. It is generally well-tolerated, with few side effects.
Some companies in the Certolizumab market include UCB, Pfizer, and AbbVie. Show Less Read more
